Home / Psoriasis (page 3)

Psoriasis

Here you will find the latest clinical research on psoriasis.

Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care

Secukinumab

Abstract Background Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has demonstrated efficacy and safety in patients with moderate to severe psoriasis. However, as per study protocols, transition periods from prior psoriasis treatments of a defined minimal length were required and use of concomitant psoriasis medication was prohibited. There is therefore …

Read More »

Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis

etanercept

Background EGALITY was a phase III confirmatory efficacy and safety study conducted in patients with plaque-type psoriasis as a part of totality of evidence gathered during the development of GP2015, an etanercept biosimilar. Objective To demonstrate equivalent efficacy and comparable safety and immunogenicity of GP2015 and the etanercept originator product …

Read More »

How Safe Are Various Systemic Therapies for Pediatric Psoriasis?

Pediatric Psoriasis

NEW YORK (Reuters Health) – For children with psoriasis, adverse events (AEs) occur less frequently with tumor necrosis factor (TNF) inhibitors than with methotrexate, but appropriate folic acid administration may mitigate the latter’s gastrointestinal effects, researchers suggest. “Our understanding of the immune changes in skin that lead to psoriasis has …

Read More »

Association between circulating prolactin levels and psoriasis and its correlation with disease severity: A meta-analysis

prolactin-levels

Lee YH, et al. – The correlation between circulating prolactin (PRL) levels and psoriasis, and between serum/plasma PRL levels and psoriasis severity was comprehensively assessed in this trial. Higher circulating PRL levels were discovered in patients with psoriasis. It was inferred that PRL levels could associate with psoriasis severity. Methods …

Read More »

IL-23 Blocker for Psoriasis Successful in Extension Trials

Tildrakizumab

GENEVA — Tildrakizumab, an investigational interleukin (IL)-23p19 inhibitor, appears to be effective for the treatment of chronic plaque psoriasis, according to long-term extensions of two phase 3 trials: reSURFACE1 and reSURFACE2 (Lancet. 2017;390:276-288). More than 80% of patients treated with tildrakizumab 200 mg for 2 years achieved a 75% reduction …

Read More »

Apremilast in psoriasis – A prospective real-world study

Apremilast

Vujic I, et al. – This paper strived to characterize psoriasis patients treated with apremilast in a real-world setting. In addition, it estimated the drug survival as a significant measure of efficacy and compliance. Variations were disclosed between real-world and trial patients. Nevertheless, apremilast was found to be safe and …

Read More »

Secukinumab safe and effective through 5 years in psoriasis

secukinumab

The improved skin clearance and favorable safety profile achieved with the interleukin-17A (IL-17A) inhibitor secukinumab is maintained through at least five years of treatment, new data suggest. The findings, presented here at the 26th European Academy of Dermatology and Venereology (EADV) Congress in Geneva, are based on the patients originally …

Read More »

Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis

Biologics

Abstract Background Biologics have greatly improved psoriasis management. However, primary and secondary non-response to treatment requires innovative strategies to optimize outcomes. Objective To describe the use of combined treatment of biologics with conventional systemic agents or phototherapy in daily clinical practice. Methods We collected data on frequency of use, demographics, …

Read More »

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)

ixekizumab

Blauvelt A, et al. – This paper scrutinized the efficacy and safety of ixekizumab through 108 weeks of treatment for moderate-to-severe plaque psoriasis. It was concluded that ixekizumab was well tolerated. It illustrated persistent efficacy through 108 weeks. Methods The enrollees (N = 1346) were randomized 2:2:2:1 to 80 mg …

Read More »